to BioTechniques free email alert service to receive content updates.
Screening
Epigenetic detection reagents
PerkinElmer's epigenetic detection reagents portfolio is specifically validated for drug discovery and life sciences research.
The screening assays for epigenetics are built upon the company's proprietary homogeneous assay platforms, Lance Ultra detection assays for peptide substrates and AlphaLISA detection assays for both peptide or full-length proteins. Both platforms are no-wash, non-radioactive , antibody-based technologies, that offer a unique combination of specificity, sensitivity, dynamic range, and throughput. All are validated for mark specificity, providing the sensitivity to work with low substrate and enzyme concentrations, generating robust and reproducible assay signals. PerkinElmer’s epigenetic and post-translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs), and deacetylases (HDACs).
 
This Product is made by:

PerkinElmer is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. Combining operational excellence and technology expertise with an intimate understanding of its customers' needs, PerkinElmer provides products and services to customers who require innovation, precision and reliability. The company is a leading provider of scientific instruments, consumables and services to the pharmaceutical, biomedical, environmental testing and general industrial markets.